News

Novo Nordisk in pact with Septerna for oral obesity drugs
Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more ...
USA Today1mon
Drugmaker Novo Nordisk warns consumers about counterfeit versions of Ozempic in US
April 14 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Monday several ... More: Taking Ozempic for weight loss? You might find other benefits, too - and a few risks Novo has advised ...